Early Access Program (EAP)

About SPOC Biosciences

SPOC Biosciences is an early-stage biotech founded in 2020, pioneering a high-throughput proteomics platform that integrates on-chip protein synthesis with real-time biosensing. Its core technology, the SPOC Platform, is designed to produce and characterize thousands of proteins simultaneously, promising a 100x scale improvement and a 90% cost reduction over conventional recombinant protein workflows. The company is currently in a pre-revenue, platform development stage, offering early access to select customers to generate large-scale kinetic data critical for AI drug discovery and therapeutic optimization.

About Sedana Medical

Sedana Medical's mission is to make inhaled sedation a standard therapy in intensive care, representing a significant shift from decades of IV sedation dominance. The company has achieved commercial traction in Europe with its integrated device-pharma platform, reporting 179 MSEK in 2024 sales, and is actively pursuing U.S. market entry through an Early Access Program. Its strategy focuses on direct sales in key European markets, expanding global distribution, and generating clinical evidence to drive adoption and achieve profitability in its ex-U.S. operations.

Therapeutic Areas